HPV16 E7 (86-93) (TFA)

HPV16 E7 (86-93) (TFA)

• UNSPSC Description: HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas[1][2].
• Target Antigen: HPV
• Type: Peptides
• Related Pathways: Anti-infection
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/hpv16-e7-86-93-tfa.html
• Purity: 99.54
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 6.67 mg/mL (ultrasonic)
• Smiles: CC[C@H](C)[C@@H](C(O)=O)NC([C@H]1N(C([C@H](CS)NC([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC(CNC([C@H](CC(C)C)NC([C@H]([C@H](O)C)N)=O)=O)=O)=O)=O)=O)CCC1)=O.OC(C(F)(F)F)=O
• Molecular Weight: 929.06
• References & Citations: [1]Hoffmann TK, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2006 Apr 15;118(8):1984-91.|[2]Cheng WF, et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology. 2005 May;115(1):136-49.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported